《人血白蛋白用于肝硬化治疗的快速建议指南》解读  

Expert consensus on Rapid Advice Guidelines for the Pharmacological Management of Human Albumin in Patients with Liver Cirrhosis

作　　者：李慧博[1,3] 门鹏 王宇[4] 徐小元 贾继东[4] 段钟平[6] 胥婕[2] 朱珠 赵志刚[8] 陈耀龙[9,10] 翟所迪[1,3] LI Hui-bo;MEN Peng;WANG Yu;XU Xiao-yuan;JIA Ji-dong;DUAN Zhong-ping;XU Jie;ZHU Zhu;ZHAO Zhi-gang;CHEN Yaolong;ZHAI Suo-di(Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;Chinese GRADE Center,Lanzhou University,Lanzhou 730000,China;Department of Infectious Diseases,Peking University Third Hospital,Beijing 100191,China;Institute for Drug Evaluation,Peking University Health Science Center,Beijing 100191,China;Liver Research Center,Beijing Friendship Hospital,Capital Medical University,Beijing 100069,China;Department of Infectious Diseases,Peking University First Hospital,Beijing 100034,China;Department of Gastroenterology and Hepatology,YouAn Hospital,Capital Medical University,Beijing 100069,China;Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing 100050,China;Evidence-Based Medicine Center,School of Basic Medical Sciences,Lanzhou University,Lanzhou 730000,China)

机构地区：[1]北京大学第三医院药剂科,北京100191 [2]北京大学第三医院感染疾病科,北京100191 [3]北京大学医学部药物评价中心,北京100191 [4]首都医科大学附属北京友谊医院肝病研究中心,北京100069 [5]北京大学第一医院感染疾病科,北京100034 [6]首都医科大学附属北京佑安医院肝病消化中心,北京100069 [7]中国医学科学院北京协和医院药剂科,北京100730 [8]首都医科大学附属北京天坛医院药学部,北京100050 [9]兰州大学循证医学中心,兰州大学基础医学院,兰州730000 [10]中国GRADE中心,兰州大学,兰州730000

出　　处：《临床药物治疗杂志》2018年第12期10-16,共7页Clinical Medication Journal

基　　金：杰特贝林(上海)医药信息咨询有限公司为本项目提供资金支持

摘　　要：为了促进人血白蛋白的临床合理应用,中国药学会医院药学专业委员会联合中华医学会肝病学分会共同制订了国内首部基于循证医学的《人血白蛋白用于肝硬化治疗的快速建议指南》。在指南制订过程中,充分考虑了指南推荐意见在临床实践中的可行性,从白蛋白的血浆浓度、低蛋白血症所造成的功能障碍以及病理生理异常诸方面,制订了人血白蛋白的应用原则和推荐剂量,以期为临床医师及药师合理应用人血白蛋白提供基本规范和具体指导。本文将主要对指南形成的推荐意见、证据总结以及推荐说明进行解读。In order to implement appropriate HA use,the Chinese Hospital Association,Chinese Society of Clinical Pharmacy and Chinese Society of Hepatology,Chinese Medical Association have developed evidence-based,Rapid Advice Guidelines for the Pharmacological Management of HA in Patients with Liver Cirrhosis.In the guideline development process,the feasibility of the guideline recommendations in clinical practice was fully considered.From the plasma concentration of albumin,dysfunction and pathophysiological abnormalities caused by hypoproteinemia,application principles and recommended dosages are intended to provide basic specifications and specific guidance for clinicians and pharmacists to rationally apply human albumin.This article will mainly explain the recommendations,evidence summary and recommendation descriptions formed by the guideline.

关 键 词：人血白蛋白 肝硬化 快速建议指南 推荐意见 

分 类 号：R975.5[医药卫生—药品]